{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:40:31Z","timestamp":1783942831749,"version":"3.55.0"},"reference-count":95,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Comorbidity and risk factor management and avoiding stroke are pillars of optimal atrial fibrillation management. In this article, the latest literature on additional stroke risk factors not included in the CHA2DS2-VA score is reviewed in patients with non-valvular atrial fibrillation (NVAF). The possible clinical impacts of the additional risk factors in NVAF patients with a CHA2DS2-VA score of 1 are compiled with insights in an interdisciplinary panel discussion to refine daily clinical practice. Methods: The panel was composed of three cardiologists, one endocrinologist, and a nephrologist. The panel members finalized twenty open-ended questions covering major problems in stroke risk stratification in NVAF patients with a score of 1. The shortcomings of this clinical-based model for stroke prevention and its possible outcomes were discussed with evidence-based recommendations. The meeting outcomes are addressed for daily clinical adaptation in the present article. Results: Recent evidence suggests that the CHA2DS2-VA score may have shortcomings in a striking rate of NVAF patients with a score of 1. The growing body of evidence suggests that combining clinical, laboratory, and imaging predictors with the CHA2DS2-VA score may further refine stroke risk prediction and aid in decision-making for anticoagulation of NVAF patients with a score of 1. Conclusions: The interdisciplinary expert panel offered several recommendations based on the assessment of additional risk factors, which may enable clinicians to identify individualized patient characteristics and early multidisciplinary prevention of disease progression and personalized improvements in the long-term cardiovascular outcomes in NVAF patients with a CHA2DS2-VA score of 1.<\/jats:p>","DOI":"10.3390\/jcm15051758","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:31:32Z","timestamp":1772098292000},"page":"1758","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Additional Stroke Risk Factors Beyond the CHA2DS2-VA Score in Non-Valvular Atrial Fibrillation: An Interdisciplinary Expert Opinion"],"prefix":"10.3390","volume":"15","author":[{"given":"Ersin \u00c7agr\u0131","family":"Simsek","sequence":"first","affiliation":[{"name":"Cardiology Clinic, Health Sciences University, \u0130zmir Tepecik Education and Research Hospital, 35120 \u0130zmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sena","family":"Sert Sekerci","sequence":"additional","affiliation":[{"name":"Cardiology Clinic, Altunizade Ac\u0131badem Hospital, 34662 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Gucun","sequence":"additional","affiliation":[{"name":"Nephrology Clinic, Ko\u015fuyolu High Specialization Education and Research Hospital, 34865 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9220-6118","authenticated-orcid":false,"given":"Seher","family":"Tanrikulu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Ac\u0131badem Ata\u015fehir Hospital, 34750 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine","family":"Dundar Ahi","sequence":"additional","affiliation":[{"name":"Primary Care Medical Team, Pfizer T\u00fcrkiye, 34394 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8751-6664","authenticated-orcid":false,"given":"Begum","family":"Ozdengulsun","sequence":"additional","affiliation":[{"name":"Primary Care Medical Team, Pfizer T\u00fcrkiye, 34394 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dursun","family":"Aras","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Medipol University Hospital, 34196 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/2047487316676037","article-title":"European Heart Rhythm Association (EHRA)\/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) Position Paper on How to Prevent Atrial Fibrillation Endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS)","volume":"24","author":"Gorenek","year":"2017","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1747493019897870","article-title":"Global Epidemiology of Atrial Fibrillation: An Increasing Epidemic and Public Health Challenge","volume":"16","author":"Lippi","year":"2021","journal-title":"Int. J. Stroke"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"102181","DOI":"10.1016\/j.cpcardiol.2023.102181","article-title":"Atrial Fibrillation and Stroke: State-of-the-Art and Future Directions","volume":"49","author":"Elsheikh","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Rienstra","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Sgarra, L., Desantis, V., Matteucci, A., Caccavo, V.P., Troisi, F., Di Monaco, A., Mangini, F., Katsouras, G., Guaricci, A.I., and Dadamo, M.L. (2025). Non-Anticoagulation Strategies Aimed at Primary Stroke Prevention in Nascent Atrial Fibrillation. Biomedicines, 13.","DOI":"10.3390\/biomedicines13030660"},{"key":"ref_7","first-page":"734","article-title":"Demographics, Treatment and Outcomes of Atrial Fibrillation in a Developing Country: The Population-Based TuRkish Atrial Fibrillation (TRAF) Cohort","volume":"19","author":"Yavuz","year":"2017","journal-title":"EP Eur."},{"key":"ref_8","first-page":"272","article-title":"Antithrombotic Treatment Patterns and Stroke Prevention in Patients with Atrial Fibrillation in TURKEY: Inferences from GARFIELD-AF Registry","volume":"21","year":"2019","journal-title":"Anatol. J. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1016\/j.jacc.2019.10.040","article-title":"Ischemic Stroke Risk in Patients with Nonvalvular Atrial Fibrillation","volume":"74","author":"Alkhouli","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/ehjcvp\/pvz016","article-title":"Oral Anticoagulation in Patients with Non-Valvular Atrial Fibrillation and a CHA2DS2-VASc Score of 1: A Current Opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke","volume":"5","author":"Sulzgruber","year":"2019","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1536\/ihj.18-174","article-title":"Antithrombotic Treatment May Reduce Mortality Among New-Onset Atrial Fibrillation Patients with Gray-Zone Risk of Stroke: A Population-Based Cohort Study","volume":"60","author":"Cheng","year":"2019","journal-title":"Int. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/00015385.2020.1720197","article-title":"Anticoagulation for Atrial Fibrillation Patients with the CHA2DS2-VASc Score = 1 (beyond Sex)","volume":"76","author":"Xie","year":"2021","journal-title":"Acta Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Proietti, M., Vitolo, M., Harrison, S.L., Lane, D.A., Fauchier, L., Marin, F., Nabauer, M., Potpara, T.S., Dan, G.-A., and Boriani, G. (2021). Impact of Clinical Phenotypes on Management and Outcomes in European Atrial Fibrillation Patients: A Report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. BMC Med., 19.","DOI":"10.1093\/ehjci\/ehaa946.2834"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Vitolo, M., Proietti, M., Shantsila, A., Boriani, G., and Lip, G.Y.H. (2021). Clinical Phenotype Classification of Atrial Fibrillation Patients Using Cluster Analysis and Associations with Trial-Adjudicated Outcomes. Biomedicines, 9.","DOI":"10.3390\/biomedicines9070843"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacc.2014.11.046","article-title":"Should Atrial Fibrillation Patients with 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex) Receive Oral Anticoagulation?","volume":"65","author":"Chao","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11886-019-1189-6","article-title":"Stroke Risk in Atrial Fibrillation: Beyond the CHA2DS2-VASc Score","volume":"21","author":"Jagadish","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_18","first-page":"229","article-title":"Should Atrial Fibrillation Patients with Hypertension as an Additional Risk Factor of the CHA2DS2-VASc Score Receive Oral Anticoagulation?","volume":"15","author":"Wang","year":"2018","journal-title":"J. Geriatr. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/heartjnl-2024-324685","article-title":"Association between NT-proBNP Levels and Risk of Atrial Fibrillation: A Systematic Review and Meta-Analysis of Cohort Studies","volume":"111","author":"Wang","year":"2025","journal-title":"Heart"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1161\/STROKEAHA.115.012609","article-title":"Ischemic Stroke Risk in Patients with Atrial Fibrillation and CHA2 DS2 -VASc Score of 1: Systematic Review and Meta-Analysis","volume":"47","author":"Joundi","year":"2016","journal-title":"Stroke"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/CRD.0000000000000246","article-title":"Should Every Patient with Atrial Fibrillation and a CHA2DS2-VASc Score of 1 Be Anticoagulated? A Systematic Review of 37,030 Patients","volume":"27","author":"Neefs","year":"2019","journal-title":"Cardiol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1016\/j.hrthm.2015.07.017","article-title":"Patients with Atrial Fibrillation and CHA2DS2-VASc Score 1: \u201cTo Anticoagulate or Not to Anticoagulate? That Is the Question!\u201d","volume":"12","author":"Patti","year":"2015","journal-title":"Heart Rhythm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.2459\/JCM.0000000000001461","article-title":"The Gray Areas of Oral Anticoagulation for Prevention of Thromboembolic Events in Atrial Fibrillation Patients","volume":"24","author":"Curcio","year":"2023","journal-title":"J Cardiovasc. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kakkar, A.K., Mueller, I., Bassand, J.-P., Fitzmaurice, D.A., Goldhaber, S.Z., Goto, S., Haas, S., Hacke, W., Lip, G.Y.H., and Mantovani, L.G. (2013). Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063479"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.tcm.2018.11.003","article-title":"How Do Aging and Comorbidities Impact Risk of Ischemic Stroke in Patients with Atrial Fibrillation","volume":"29","author":"Liao","year":"2019","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, Regional, and National Burden of Chronic Kidney Disease, 1990\u20132017: A Systematic Analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.kint.2017.11.019","article-title":"Primary Outcomes of the Monitoring in Dialysis Study Indicate That Clinically Significant Arrhythmias Are Common in Hemodialysis Patients and Related to Dialytic Cycle","volume":"93","author":"Tumlin","year":"2018","journal-title":"Kidney Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1093\/eurheartj\/ehab301","article-title":"Atrial Fibrillation and Chronic Kidney Disease","volume":"42","author":"Benn","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.31083\/j.rcm2504143","article-title":"Atrial Fibrillation and Chronic Kidney Disease: Aetiology and Management","volume":"25","author":"Sidhu","year":"2024","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.107.716951","article-title":"High Absolute Risks and Predictors of Venous and Arterial Thromboembolic Events in Patients with Nephrotic Syndrome: Results from a Large Retrospective Cohort Study","volume":"117","author":"Mahmoodi","year":"2008","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.amjmed.2021.11.018","article-title":"Risk of Arterial Thromboembolism, Venous Thromboembolism, and Bleeding in Patients with Nephrotic Syndrome: A Population-Based Cohort Study","volume":"135","author":"Vestergaard","year":"2022","journal-title":"Am. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.thromres.2005.03.030","article-title":"Thromboembolic Complications in the Nephrotic Syndrome: Pathophysiology and Clinical Management","volume":"118","author":"Singhal","year":"2006","journal-title":"Thromb. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJMcibr1209459","article-title":"Venous Thrombosis in the Nephrotic Syndrome","volume":"368","author":"Loscalzo","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.112.107128","article-title":"Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation: Validation of the R2 CHADS2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk Factors In Atrial Fibrillation) Study Cohorts","volume":"127","author":"Piccini","year":"2013","journal-title":"Circulation"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e000250","DOI":"10.1161\/JAHA.113.000250","article-title":"A New Risk Scheme to Predict Ischemic Stroke and Other Thromboembolism in Atrial Fibrillation: The ATRIA Study Stroke Risk Score","volume":"2","author":"Singer","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.111.020982","article-title":"Chronic Kidney Disease Is Associated with the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study","volume":"123","author":"Alonso","year":"2011","journal-title":"Circulation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.jacc.2019.08.1031","article-title":"Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation","volume":"74","author":"Kumar","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e13745","DOI":"10.1111\/eci.13745","article-title":"Impact of Renal Impairment on Atrial Fibrillation: ESC-EHRA EORP-AF Long-Term General Registry","volume":"52","author":"Ding","year":"2022","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Dimitrijevic, Z.M., Mitic, B.P., Tasic, D.D., Vrecic, T., Paunovic, K., and Salinger, S. (2024). Bleeding and Thrombotic Events in Hemodialysis Patients with Atrial Fibrillation on Anticoagulation and Antiplatelet Therapy: A 24-Month Cohort Study. Medicina, 60.","DOI":"10.3390\/medicina60111760"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1253\/circj.CJ-13-1246","article-title":"Impact of Renal Dysfunction on Clinical Outcome in Patients with Low Risk of Atrial Fibrillation","volume":"78","author":"Lin","year":"2014","journal-title":"Circ. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e000568","DOI":"10.1136\/openhrt-2016-000568","article-title":"Comparison of the Chronic Kidney Disease Epidemiology Collaboration, the Modification of Diet in Renal Disease Study and the Cockcroft-Gault Equation in Patients with Heart Failure","volume":"4","author":"Szummer","year":"2017","journal-title":"Open Heart"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/heartjnl-2016-309266","article-title":"Warfarin Utilisation and Anticoagulation Control in Patients with Atrial Fibrillation and Chronic Kidney Disease","volume":"103","author":"Yang","year":"2017","journal-title":"Heart"},{"key":"ref_44","first-page":"1612","article-title":"2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"EP Eur."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial","volume":"32","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for Patients with Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jtha.2023.09.020","article-title":"Anticoagulation in Chronic Kidney Disease: Current Status and Future Perspectives","volume":"22","author":"Jones","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, Regional, and National Prevalence of Adult Overweight and Obesity, 1990\u20132021, with Forecasts to 2050: A Forecasting Study for the Global Burden of Disease Study 2021","volume":"405","author":"Ng","year":"2025","journal-title":"Lancet"},{"key":"ref_49","unstructured":"(2025, June 16). Turkish Statistical Institute Turkish Health Research, Available online: https:\/\/data.tuik.gov.tr\/Bulten\/Index?p=Turkey-Health-Survey-2019-33661."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/ehjcvp\/pvae064","article-title":"Update on Antithrombotic Therapy and Body Mass: A Clinical Consensus Statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiology Working Group on Thrombosis","volume":"10","author":"Gigante","year":"2024","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus Warfarin in Patients with Atrial Fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus Warfarin in Patients with Atrial Fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus Warfarin in Patients with Atrial Fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/eurheartj\/ehy861","article-title":"Relationship between Body Mass Index and Outcomes in Patients with Atrial Fibrillation Treated with Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial","volume":"40","author":"Boriani","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1046\/j.1523-1755.1999.00389.x","article-title":"Influence of Excess Weight on Mortality and Hospital Stay in 1346 Hemodialysis Patients","volume":"55","author":"Fleischmann","year":"1999","journal-title":"Kidney Int."},{"key":"ref_57","first-page":"1489","article-title":"Direct-Acting Oral Anticoagulant Choice for Stroke Prevention in Obese Patients with Atrial Fibrillation","volume":"37","author":"Brar","year":"2021","journal-title":"Can. J. Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Karakasis, P., Ktenopoulos, N., Pamporis, K., Sagris, M., Soulaidopoulos, S., Gerogianni, M., Leontsinis, I., Giannakoulas, G., Tousoulis, D., and Fragakis, N. (2024). Efficacy and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients (BMI \u2265 30 Kg\/M2) with Atrial Fibrillation or Venous Thromboembolism: An Updated Systematic Review and Meta-Analysis. J. Clin. Med., 13.","DOI":"10.3390\/jcm13133784"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Deitelzweig, S., Keshishian, A., Kang, A., Dhamane, A.D., Luo, X., Li, X., Balachander, N., Rosenblatt, L., Mardekian, J., and Pan, X. (2020). Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061633"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2352-3026(19)30086-9","article-title":"Efficacy and Safety of Direct Oral Factor Xa Inhibitors Compared with Warfarin in Patients with Morbid Obesity: A Single-Centre, Retrospective Analysis of Chart Data","volume":"6","author":"Kushnir","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/1358863X241264478","article-title":"Comparing DOAC and Warfarin Outcomes in an Obese Population Using the \u2018Real-World\u2019 Michigan Anticoagulation Quality Improvement Initiative (MAQI2) Registry","volume":"29","author":"Ardeshna","year":"2024","journal-title":"Vasc. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"euaf019","DOI":"10.1093\/europace\/euaf019","article-title":"Atrial Fibrillation Burden in Clinical Practice, Research, and Technology Development: A Clinical Consensus Statement of the European Society of Cardiology Council on Stroke and the European Heart Rhythm Association","volume":"27","author":"Doehner","year":"2025","journal-title":"Europace"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1093\/eurheartj\/ehae373","article-title":"Atrial Fibrillation Burden: A New Outcome Predictor and Therapeutic Target","volume":"45","author":"Becher","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ijcard.2016.12.189","article-title":"Methods, Accuracy and Clinical Implications of Atrial Fibrillation Detection by Cardiac Implantable Electronic Devices","volume":"236","author":"Solari","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cvdhj.2023.08.019","article-title":"Filtering of Remote Monitoring Alerts Transmitted by Cardiac Implantable Electronic Devices and Reclassification of Atrial Fibrillation Events by a New Algorithm","volume":"4","author":"Lazarus","year":"2023","journal-title":"Cardiovasc. Digit. Health J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1016\/j.jacc.2014.04.019","article-title":"Clinical Classifications of Atrial Fibrillation Poorly Reflect Its Temporal Persistence","volume":"63","author":"Charitos","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"939","DOI":"10.12998\/wjcc.v10.i3.939","article-title":"Atrial Fibrillation Burden and the Risk of Stroke: A Systematic Review and Dose-Response Meta-Analysis","volume":"10","author":"Yang","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1540-8167.2008.01320.x","article-title":"Presence and Duration of Atrial Fibrillation Detected by Continuous Monitoring: Crucial Implications for the Risk of Thromboembolic Events","volume":"20","author":"Botto","year":"2009","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jacc.2003.08.027","article-title":"Long-Term Risk of Recurrent Atrial Fibrillation as Documented by an Implantable Monitoring Device","volume":"43","author":"Israel","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ahj.2004.06.032","article-title":"Asymptomatic Atrial Fibrillation: Demographic Features and Prognostic Information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study","volume":"149","author":"Flaker","year":"2005","journal-title":"Am. Heart J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa2310234","article-title":"Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation","volume":"390","author":"Healey","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1161\/CIRCULATIONAHA.113.007825","article-title":"Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events","volume":"129","author":"Brambatti","year":"2014","journal-title":"Circulation"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"I89","DOI":"10.1093\/eurheartjsupp\/suac079","article-title":"Ischaemic Stroke in the Absence of Documented Atrial Fibrillation: Is There Who Could Benefit from Anticoagulant Therapy?","volume":"24","year":"2022","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1161\/CIRCULATIONAHA.109.873265","article-title":"N-Terminal Pro-B-Type Natriuretic Peptide Is a Major Predictor of the Development of Atrial Fibrillation: The Cardiovascular Health Study","volume":"120","author":"Patton","year":"2009","journal-title":"Circulation"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1080\/1354750X.2018.1463562","article-title":"Relationship of Troponin to Incident Atrial Fibrillation Occurrence, Recurrence after Radiofrequency Ablation and Prognosis: A Systematic Review, Meta-Analysis and Meta-Regression","volume":"23","author":"Bai","year":"2018","journal-title":"Biomarkers"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1373\/clinchem.2014.226936","article-title":"Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy","volume":"61","author":"Hijazi","year":"2015","journal-title":"Clin. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1161\/CIRCULATIONAHA.111.038729","article-title":"Cardiac Biomarkers Are Associated with an Increased Risk of Stroke and Death in Patients with Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy","volume":"125","author":"Hijazi","year":"2012","journal-title":"Circulation"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/eurheartj\/ehw054","article-title":"The ABC (Age, Biomarkers, Clinical History) Stroke Risk Score: A Biomarker-Based Risk Score for Predicting Stroke in Atrial Fibrillation","volume":"37","author":"Hijazi","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/ejhf.2946","article-title":"Practical Algorithms for Early Diagnosis of Heart Failure and Heart Stress Using NT-proBNP: A Clinical Consensus Statement from the Heart Failure Association of the ESC","volume":"25","author":"Docherty","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"D278","DOI":"10.1093\/eurheartjsupp\/suad106","article-title":"ANMCO Position Paper on Vericiguat Use in Heart Failure: From Evidence to Place in Therapy","volume":"25","author":"Alonzo","year":"2023","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.jacc.2006.02.048","article-title":"Left Atrial Size","volume":"47","author":"Abhayaratna","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/205013","article-title":"Left Atrial Appendage: Physiology, Pathology, and Role as a Therapeutic Target","volume":"2015","author":"Regazzoli","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"He, W., Yin, L., Liu, Q., Zhang, Y., Zhao, Y., Wang, L., and You, L. (2024). Influencing Factors and Predictive Model for Left Atrial Appendage Emptying Velocity in Nonvalvular AF Patients. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1468379"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1540-8167.2010.01814.x","article-title":"Left Atrial Appendage Studied by Computed Tomography to Help Planning for Appendage Closure Device Placement","volume":"21","author":"Wang","year":"2010","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e022274","DOI":"10.1161\/JAHA.121.022274","article-title":"Left Atrial Appendage Occlusion for Stroke Prevention in Nonvalvular Atrial Fibrillation","volume":"10","author":"Collado","year":"2021","journal-title":"J. Am. Hear. Assoc."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jacc.2012.04.032","article-title":"Does the Left Atrial Appendage Morphology Correlate with the Risk of Stroke in Patients with Atrial Fibrillation?","volume":"60","author":"Santangeli","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijcha.2015.05.012","article-title":"Incidence of Thromboembolism Following Detection by Trans-Oesophageal Echocardiography of Left Atrial Thrombus","volume":"8","author":"Mahon","year":"2015","journal-title":"IJC Heart Vasc."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"101210","DOI":"10.1016\/j.jacadv.2024.101210","article-title":"Atrial Fibrillation in Hypertrophic Cardiomyopathy","volume":"3","author":"Saberi","year":"2024","journal-title":"JACC Adv."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.chest.2016.09.014","article-title":"OSA and Cardiac Arrhythmogenesis: Mechanistic Insights","volume":"151","author":"May","year":"2017","journal-title":"Chest"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1161\/STROKEAHA.120.030285","article-title":"Impact of Sleep Apnea on Cardioembolic Risk in Patients with Atrial Fibrillation: Data from the ESADA Cohort","volume":"52","author":"Pengo","year":"2021","journal-title":"Stroke"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/CIRCOUTCOMES.111.964783","article-title":"Association of Obstructive Sleep Apnea with Risk of Serious Cardiovascular Events: A Systematic Review and Meta-Analysis","volume":"5","author":"Loke","year":"2012","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejim.2024.12.020","article-title":"Effect of Continuous Positive Airway Pressure on Non-Fatal Stroke and Paroxysmal Atrial Fibrillation Recurrence in Obstructive Sleep Apnoea Elderly Patients","volume":"133","author":"Condoleo","year":"2025","journal-title":"Eur. J. Intern. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMoa1606599","article-title":"CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea","volume":"375","author":"McEvoy","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jce.70152","article-title":"Catheter Ablation Is Associated with a Decrease in Major Adverse Cardiovascular Events and All-Cause Mortality in Patients with Atrial Fibrillation and Obstructive Sleep Apnea","volume":"37","author":"Bidaoui","year":"2026","journal-title":"J. Cardiovasc. Electrophysiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/5\/1758\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:04:21Z","timestamp":1772100261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/5\/1758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":95,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["jcm15051758"],"URL":"https:\/\/doi.org\/10.3390\/jcm15051758","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]}}}